BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.

XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

PNW fourth-quarter earnings decrease year over year, while revenues increase. Total operating expenses also rise during the same period.

IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra...

UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues...